SHANGHAI, Nov. 3, 2015 /PRNewswire/ -- L.E.K. Consulting, a global management consulting firm, recently published a guidebook dedicated for China outbound investment in the biopharmaceutical/biotech/healthcare sectors: From China to the World: An Investment and Market Access Guide for Chinese Biopharmaceutical Companies. Entrusted by Shanghai Municipal Commission of Commerce, this guidebook, a culmination of work by L.E.K. Consulting, with legal advice from Clifford Chance, is intended to provide Chinese business leaders in the sectors with concise information on the issues and opportunities regarding outbound investment and partnerships for direct investment abroad, or to bring technology back home.
The guidebook consolidates the latest thinking and first-hand experience from industry thought leaders, practitioners and L.E.K. global experts. It provides insights into current state of Chinese biopharma outbound investment activities and lessons learned from case studies. A thorough review of investment environment, opportunities and challenges of 9 major countries, and a list of useful tools and "how-to" approach for planning, execution and post-deal integration. The book also highlights the common risks in going overseas, and it provides practical advice so that business leaders can be more confident in making investment decisions and ultimately successful on the path toward internationalization.
In order to support the "going overseas" strategy of Shanghai enterprises and to promote the sustainable development of outbound investment and international cooperation, Shanghai Municipal Commission of Commerce engaged professional service firms to compile outbound investment guidebooks focusing on four hot industries of outbound investment. These book aims to provide directional information and reference for Shanghai enterprises' decision-making. Along with the biotechnology developments driven by the trend of aging population around the globe, the growing demand within China's domestic market, and the accelerating pace of China's outbound investment. The biopharmaceutical sector is increasingly becoming a focused industry for Chinese enterprises' overseas investment activities.
"This guidebook compiles informative content and insightful views of numerous market experts and business leaders," said Justin Wang, an editor of the guidebook and managing director at L.E.K. Consulting. "It includes not only an introductory overview of various overseas markets but also discusses many strategic issues and provides practical suggestions. We hope that this book will be a useful resource and help Chinese enterprises' decision-makers propel their business forward and succeed in the 'going overseas' journey!"
The full guidebook is available in Chinese only and can be downloaded by clicking [HERE]. If you are interested in more cdetails, please ontact Anita Chen at +86 21 6122 3918 or a.chen@lek.com.
Scan QR code below to follow L.E.K. China on WeChat for more insights and news.
About Clifford Chance
Clifford Chance is one of the world's pre-eminent law firms, with significant depth and range of resources across five continents. The firm counsels a broad range of clients, including corporates from all the commercial and industrial sectors, governments, regulators, trade bodies and not-for-profit organizations. Clifford chance seeks to provide clients with the highest-quality advice and legal insight, which combines the firm's global standards with in-depth local expertise.
About Shanghai Municipal Commission of Commerce
Shanghai Municipal Commission of Commerce is a department under Shanghai Municipal Government, responsible "going overseas" support for Shanghai enterprises. In 2014, via the approach of public procurement of professional service, Shanghai Municipal Commission of Commerce aims to enhance the public-service system construction for "going overseas" support, leverage the strengths of professional service agencies, provide professional and effective support to 'going overseas' enterprises, promote the long-term development of the city's outbound investment and cooperation, bring the 'going overseas' support to a higher level and broader territory.
About L.E.K. Consulting
L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries -- including the largest private and public sector organizations, private equity firms and emerging entrepreneurial businesses. Founded more than 30 years ago, L.E.K. employs more than 1,000 professionals across the Americas, Asia-Pacific and Europe. For more information, go to www.lek.com.
Appendix I
Introduction to the International Biopharmaceutical Investment Guide
This reference book is a culmination of work by strategy advisor L.E.K. Consulting and law firm Clifford Chance. It is intended to provide Chinese business leaders with concise information on the issues and opportunities regarding outbound investment and partnerships in the biopharmaceutical/biotech/healthcare sectors for direct investment abroad, or to bring technology back home.
L.E.K. Consulting is a global strategy consulting firm with offices across Europe, the Americas and Asia-Pacific, and the leading commercial advisor to life sciences companies. This book is based on the firm's extensive global work advising clients on their key strategic issues, and using analytical rigor to help them make informed decisions more quickly and solve their toughest and most critical business problems. Furthermore, the book leverages the firm's experience helping clients implement strategic recommendations and understanding of the rigorous processes and skills necessary to be successful in today's ever-changing global marketplace.
Clifford Chance is one of the world's pre-eminent law firms, with significant depth and range of resources across five continents. The firm counsels a broad range of clients, including corporates from all the commercial and industrial sectors, governments, regulators, trade bodies and not-for-profit organizations. Clifford Chance seeks to provide clients with the highest-quality advice and legal insight, which combines the firm's global standards with in-depth local expertise.
In order to capture the latest thinking and trends on Chinese outbound investment, we spoke with our colleagues around the world who deal with these matters on a daily basis. Contributors include CEOs, presidents, law firm partners, financial advisors, and physicians. In addition, we researched published articles by industry leaders and spoke with many of them to capture their perspectives. Furthermore, we interviewed executives from numerous Chinese pharmaceutical companies, who provided valuable input and contributions. These conversations highlight lessons learned in their business dealings in international markets, from United States to Australia. Finally, L.E.K. Consulting's internal experts and thought leaders reviewed all the material to ensure the readers would have the most useful and current information.
The book is divided into nine major sections. The first two sections provide insights into the current state of Chinese biopharma companies' foreign investment, including market activity, opportunities and challenges. It also covers the strategy of international expansion, including lessons from successful pharmaceutical companies and research from L.E.K.'s work with other Chinese healthcare companies. Sections III to VI contain investment and market information for 9 key countries from major regions. In addition to these country primers, we have also included case studies, how-to summaries and lessons learned from industry insiders. These sections are intended to provide more than just facts and figures, but insights that will set you on a trajectory to successful international investment. Finally, Section VII to IX are for Chinese companies looking to take action and are focused on strategic planning, business transactions, and post-merger integration. These "how-to" sections are filled with practical advice and learnings from business executives and professional advisors who have first-hand experience with global expansion.
Photo - http://photos.prnasia.com/prnh/20151029/0861510414-a
Photo - http://photos.prnasia.com/prnh/20151029/0861510414-b
